The higher frequency of KEAP1/STK11 co-mutations in patient-derived cell lines compared with tumor datasets (Figure 2b; Table S2b) suggests a potential selective advantage for in vitro establishment, possibly because of enhanced glutamine utilization and reactive oxidative stress resistance [61]. Here, STK11 is linked to neoplasm.